Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction.

Claramunt-Taberner D, Flammier S, Gaillard S, Cochat P, Peyruchaud O, Machuca-Gayet I, Bacchetta J.

Nephrol Dial Transplant. 2018 Jan 19. doi: 10.1093/ndt/gfx362. [Epub ahead of print]

PMID:
29365190
2.

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.

Bellanger A, Donini CF, Vendrell JA, Lavaud J, Machuca-Gayet I, Ruel M, Vollaire J, Grisard E, Győrffy B, Bièche I, Peyruchaud O, Coll JL, Treilleux I, Maguer-Satta V, Josserand V, Cohen PA.

J Pathol. 2017 May;242(1):73-89. doi: 10.1002/path.4882. Epub 2017 Mar 27.

PMID:
28207159
3.

Murine models of breast cancer bone metastasis.

Wright LE, Ottewell PD, Rucci N, Peyruchaud O, Pagnotti GM, Chiechi A, Buijs JT, Sterling JA.

Bonekey Rep. 2016 May 11;5:804. eCollection 2016.

4.

The role of platelets and megakaryocytes in bone metastasis.

Leblanc R, Peyruchaud O.

J Bone Oncol. 2016 Apr 8;5(3):109-111. eCollection 2016 Sep.

5.

Metastasis: new functional implications of platelets and megakaryocytes.

Leblanc R, Peyruchaud O.

Blood. 2016 Jul 7;128(1):24-31. doi: 10.1182/blood-2016-01-636399. Epub 2016 May 6. Review.

6.

The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.

Sahay D, Leblanc R, Grunewald TG, Ambatipudi S, Ribeiro J, Clézardin P, Peyruchaud O.

Oncotarget. 2015 Aug 21;6(24):20604-20.

7.

New insights into the autotaxin/LPA axis in cancer development and metastasis.

Leblanc R, Peyruchaud O.

Exp Cell Res. 2015 May 1;333(2):183-9. doi: 10.1016/j.yexcr.2014.11.010. Epub 2014 Nov 25. Review.

PMID:
25460336
8.

Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone.

Leblanc R, Lee SC, David M, Bordet JC, Norman DD, Patil R, Miller D, Sahay D, Ribeiro J, Clézardin P, Tigyi GJ, Peyruchaud O.

Blood. 2014 Nov 13;124(20):3141-50. doi: 10.1182/blood-2014-04-568683. Epub 2014 Oct 2.

9.

Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.

David M, Sahay D, Mege F, Descotes F, Leblanc R, Ribeiro J, Clézardin P, Peyruchaud O.

PLoS One. 2014 May 14;9(5):e97771. doi: 10.1371/journal.pone.0097771. eCollection 2014.

10.

Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.

Bachelier R, Confavreux CB, Peyruchaud O, Croset M, Goehrig D, van der Pluijm G, Clézardin P.

Int J Cancer. 2014 Sep 15;135(6):1319-29. doi: 10.1002/ijc.28787. Epub 2014 Mar 3.

11.

Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.

David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Lopez Vales R, Jurdic P, Chun J, Clézardin P, Ishii M, Peyruchaud O.

J Biol Chem. 2014 Mar 7;289(10):6551-64. doi: 10.1074/jbc.M113.533232. Epub 2014 Jan 15.

12.

Pleiotropic activity of lysophosphatidic acid in bone metastasis.

Peyruchaud O, Leblanc R, David M.

Biochim Biophys Acta. 2013 Jan;1831(1):99-104. doi: 10.1016/j.bbalip.2012.06.004. Epub 2012 Jun 16. Review.

PMID:
22710393
13.

Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.

David M, Ribeiro J, Descotes F, Serre CM, Barbier M, Murone M, Clézardin P, Peyruchaud O.

Int J Oncol. 2012 Apr;40(4):1133-41. doi: 10.3892/ijo.2011.1309. Epub 2011 Dec 20.

14.

Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.

Kennedy PC, Zhu R, Huang T, Tomsig JL, Mathews TP, David M, Peyruchaud O, Macdonald TL, Lynch KR.

J Pharmacol Exp Ther. 2011 Sep;338(3):879-89. doi: 10.1124/jpet.111.181552. Epub 2011 Jun 1.

15.

Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clézardin P, Peyruchaud O.

PLoS One. 2010 Mar 17;5(3):e9741. doi: 10.1371/journal.pone.0009741.

16.

Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms.

Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clézardin P, Peyruchaud O.

Oncol Res. 2009;18(4):173-84. Erratum in: Oncol Res. 2009;18(7):357. Philippe, Clézardin [corrected to Clézardin, Philippe]; Oliver, Peyruchaud [corrected to Peyruchaud, Oliver].

PMID:
20112503
17.
18.

[Mechanisms of bone metastasis formation].

Peyruchaud O.

J Soc Biol. 2007;201(3):229-36. Review. French.

PMID:
18157074
19.

Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.

Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P, Clézardin P.

Cancer Res. 2007 Jun 15;67(12):5821-30.

20.

Family screening for a Glanzmann's thrombasthenia mutation using PCR-SSCP.

Ruan J, Peyruchaud O, Nurden P, Cazes E, Combrié R, Bourre F, Nurden AT.

Platelets. 1998;9(2):129-36.

PMID:
16793688
21.

The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clézardin P, Peyruchaud O.

Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8. Epub 2006 Jun 12.

22.

[Lysophosphatidic acid: a new link between blood platelets and bone metastasis].

Peyruchaud O, Boucharaba A, Saulnier-Blache JS, Clézardin P.

Med Sci (Paris). 2005 Apr;21(4):353-5. French. No abstract available.

23.

Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

Boucharaba A, Serre CM, Grès S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clézardin P, Peyruchaud O.

J Clin Invest. 2004 Dec;114(12):1714-25.

24.

[Does tumor angiogenesis play a role in bone metastatic process?].

Peyruchaud O, Serre CM, NicAmhlaoibh R, Sveigaard C, Clézardin P.

Rev Med Suisse Romande. 2004 Feb;124(2):83-4. French.

PMID:
15095619
25.

Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity.

Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Clezardin P.

J Biol Chem. 2003 Nov 14;278(46):45826-32. Epub 2003 Sep 3.

26.

In vitro and in vivo antitumor effects of bisphosphonates.

Clézardin P, Fournier P, Boissier S, Peyruchaud O.

Curr Med Chem. 2003 Jan;10(2):173-80. Review.

PMID:
12570716
27.

Analysis of the amino acid requirement for a normal alphaIIbbeta3 maturation at alphaIIbGlu324 commonly mutated in Glanzmann thrombasthenia.

Milet-Marsal S, Breillat C, Peyruchaud O, Nurden P, Combrié R, Nurden AT, Bourre F.

Thromb Haemost. 2002 Oct;88(4):655-62.

PMID:
12362239
28.

Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone.

Pécheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clézardin P.

FASEB J. 2002 Aug;16(10):1266-8. Epub 2002 Jun 21.

PMID:
12153995
29.

Two different beta3 cysteine substitutions alter alphaIIb beta3 maturation and result in Glanzmann thrombasthenia.

Milet-Marsal S, Breillat C, Peyruchaud O, Nurden P, Combrié R, Nurden A, Bourre F.

Thromb Haemost. 2002 Jul;88(1):104-10.

PMID:
12152649
30.
31.

Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists.

Olorundare OE, Peyruchaud O, Albrecht RM, Mosher DF.

Blood. 2001 Jul 1;98(1):117-24.

32.

Modulation of cell interactions with extracellular matrix by lysophosphatidic acid and sphingosine 1-phosphate.

Panetti TS, Magnusson MK, Peyruchaud O, Zhang Q, Cooke ME, Sakai T, Mosher DF.

Prostaglandins Other Lipid Mediat. 2001 Apr;64(1-4):93-106. Review.

PMID:
11324710
33.
34.

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.

Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P.

Cancer Res. 2000 Jun 1;60(11):2949-54.

35.

Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a Rho-dependent signal pathway.

Zhang Q, Peyruchaud O, French KJ, Magnusson MK, Mosher DF.

Blood. 1999 May 1;93(9):2984-90.

36.

R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome.

Peyruchaud O, Nurden AT, Milet S, Macchi L, Pannochia A, Bray PF, Kieffer N, Bourre F.

Blood. 1998 Dec 1;92(11):4178-87.

37.

Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia.

Ruan J, Peyruchaud O, Alberio L, Valles G, Clemetson K, Bourre F, Nurden AT.

Br J Haematol. 1998 Sep;102(4):918-25.

PMID:
9734640
38.

Linkage of four polymorphisms on the alphaIIb gene.

Ruan J, Peyruchaud O, Nurden A, Bourre F.

Br J Haematol. 1998 Jul;102(2):622-5.

PMID:
9695983
39.
40.

A three amino acid deletion in glycoprotein IIIa is responsible for type I Glanzmann's thrombasthenia: importance of residues Ile325Pro326Gly327 for beta3 integrin subunit association.

Morel-Kopp MC, Kaplan C, Proulle V, Jallu V, Melchior C, Peyruchaud O, Aurousseau MH, Kieffer N.

Blood. 1997 Jul 15;90(2):669-77.

41.

HPA-10w(b) (La(a)): genetic determination of a new platelet-specific alloantigen on glycoprotein IIIa and its expression in COS-7 cells.

Peyruchaud O, Bourre F, Morel-Kopp MC, Reviron D, Mercier P, Nurden A, Kaplan C.

Blood. 1997 Apr 1;89(7):2422-8.

42.

Efficient RT-PCR on platelet mRNA after long-term storage.

Peyruchaud O, Nurden A, Bourre F.

Br J Haematol. 1997 Jan;96(1):183-5.

PMID:
9012707
43.
44.

Non-radioactive SSCP for genotyping human platelet alloantigens.

Peyruchaud O, Nurden A, Bourre F.

Br J Haematol. 1995 Mar;89(3):633-6.

PMID:
7734366
45.

Immunodetection of the plum pox virus helper component in infected plants and expression of its gene in transgenic plants.

Ravelonandro M, Peyruchaud O, Garrigue L, de Marcillac G, Dunez J.

Arch Virol. 1993;130(3-4):251-68.

PMID:
8517789

Supplemental Content

Loading ...
Support Center